Evofem Stock Analysis

EVFM -  USA Stock  

USD 1.10  0.06  5.17%

The big decline in price over the last few months for Evofem Biosciences could raise concerns from stakeholders as the firm it trading at a share price of 1.10 on 15,676,200 in volume. The company executives failed to add value to investors and positioning the firm supply of money to exploit market volatility in May. However, diversifying your holdings with Evofem Biosciences or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 7.87. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Evofem Biosciences partners.
Continue to Investing Opportunities.

Search Stock Analysis 

 
Refresh
The Evofem Biosciences stock analysis report makes it easy to digest most publicly released information about Evofem Biosciences and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Evofem stock analysis module also helps to analyze the Evofem Biosciences price relationship with some important fundamental indicators such as market cap and management efficiency.

Evofem Stock Analysis Notes

About 36.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 2.12. Evofem Biosciences had not issued any dividends in recent years. The entity had a split on the 18th of January 2018. Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in womens sexual and reproductive health. Evofem Biosciences, Inc. is headquartered in San Diego, California. Evofem Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 147 people. To learn more about Evofem Biosciences call Saundra Pelletier at 858 550 1900 or check out http://www.evofem.com.

Evofem Biosciences Quarterly Cost of Revenue

506,000Share

Evofem Biosciences Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Evofem Biosciences' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Evofem Biosciences or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Evofem Biosciences generates negative expected return over the last 90 days
Evofem Biosciences has high historical volatility and very poor performance
Evofem Biosciences may become a speculative penny stock
Evofem Biosciences has a very high chance of going through financial distress in the upcoming years
Evofem Biosciences was previously known as Evofem Biosciences and was traded on NASDAQ Exchange under the symbol NEOT.
The company reported the previous year's revenue of 446 K. Net Loss for the year was (142.31 M) with profit before overhead, payroll, taxes, and interest of 78 K.
Evofem Biosciences currently holds about 48.89 M in cash with (104.83 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.59.
Evofem Biosciences has a frail financial position based on the latest SEC disclosures
Latest headline from finance.yahoo.com: Does Evofem Biosciences Deserve a Place in Your Portfolio - Yahoo Finance

Evofem Biosciences Upcoming and Recent Events

Earnings reports are used by Evofem Biosciences to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Evofem Biosciences previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report3rd of August 2021
Next Earnings Report8th of November 2021
Next Fiscal Quarter End30th of June 2021
Next Fiscal Year End3rd of March 2022
Last Quarter Report31st of March 2021
Last Earning Announcement30th of June 2020

Evofem Largest EPS Surprises

Earnings surprises can significantly impact Evofem Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2020-03-12
2019-12-31-0.3-0.270.0310 
2020-05-06
2020-03-31-0.3467-0.4-0.053315 
2020-11-09
2020-09-30-0.44-0.370.0715 
View All Earnings Estimates

Evofem Biosciences SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Evofem Biosciences prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Evofem Biosciences investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Evofem Biosciences specific information freely available to individual and institutional investors to make a timely investment decision.
4th of June 2021
Financial Statements and Exhibits. Regulation FD Disclosure. Unclassified Corporate Event
View
28th of May 2021
Unclassified Corporate Event
View
20th of May 2021
Unclassified Corporate Event
View
19th of May 2021
Financial Statements and Exhibits. Other Events. Entry into a Material Definitive Agreement
View
12th of May 2021
Submission of Matters to a Vote of Security Holders
View
6th of May 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
27th of April 2021
Unclassified Corporate Event
View
7th of April 2021
Financial Statements and Exhibits. Regulation FD Disclosure
View

Evofem Biosciences Thematic Classifications

In addition to having Evofem Biosciences stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Pharmaceutical Products IdeaPharmaceutical Products
USA Equities from Pharmaceutical Products industry as classified by Fama & French

Evofem Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 119.29 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Evofem Biosciences's market, we take the total number of its shares issued and multiply it by Evofem Biosciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Evofem Profitablity

Evofem Biosciences' profitability indicators refer to fundamental financial ratios that showcase Evofem Biosciences' ability to generate income relative to its revenue or operating costs. If, let's say, Evofem Biosciences is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Evofem Biosciences' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Evofem Biosciences' profitability requires more research than a typical breakdown of Evofem Biosciences' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2021
Return on Average Assets(1.53) (1.65) 
Return on Average Equity(5.12) (5.26) 
Return on Invested Capital(10.50) (10.77) 
Return on Sales(287.16) (309.83) 

Management Efficiency

The entity has return on total asset (ROA) of (93.59) % which means that it has lost $93.59 on every $100 spent on asset. This is way below average. Evofem Biosciences management efficiency ratios could be used to measure how well evofem biosciences manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return on Average Assets is estimated to pull down to -1.65. The value of Return on Average Equity is estimated to pull down to -5.26. Evofem Biosciences Average Assets are relatively stable at the moment as compared to the past year. The company's current value of Average Assets is estimated at 100.61 Million. Tangible Asset Value is expected to hike to about 118.6 M this year, although the value of Asset Turnover will most likely fall to 0.004474.
Last ReportedProjected for 2021
Book Value per Share 0.02  0.0216 
Enterprise Value over EBIT(1.00) (1.08) 
Enterprise Value over EBITDA(1.16) (1.25) 
Price to Book Value 145.42  156.91 
Tangible Assets Book Value per Share 1.64  1.68 
Enterprise Value165.1 M137 M
Tangible Asset Value110 M118.6 M

Technical Drivers

As of the 19th of June, Evofem Biosciences shows the mean deviation of 4.66, and Coefficient Of Variation of (762.62). Evofem Biosciences technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to analyze and collect data for nineteen technical drivers for Evofem Biosciences, which can be compared to its rivals. Please confirm Evofem Biosciences coefficient of variation, treynor ratio, as well as the relationship between the Treynor Ratio and semi variance to decide if Evofem Biosciences is priced favorably, providing market reflects its regular price of 1.1 per share. Given that Evofem Biosciences is a hitting penny stock territory we advise to closely look at its total risk alpha.

Evofem Biosciences Price Movement Analysis

The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. View also all equity analysis or get more info about mavp overlap studies indicator.

Evofem Biosciences Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Evofem Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Evofem Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Evofem Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Evofem Biosciences Predictive Daily Indicators

Evofem Biosciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Evofem Biosciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Evofem Biosciences Forecast Models

Evofem Biosciences time-series forecasting models is one of many Evofem Biosciences' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Evofem Biosciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Evofem Biosciences Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Evofem Biosciences stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Evofem shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Evofem Biosciences. By using and applying Evofem Stock analysis, traders can create a robust methodology for identifying Evofem entry and exit points for their positions.
Last ReportedProjected for 2021
EBITDA Margin(60.91) (65.72) 
Gross Margin(0.0441) (0.0453) 
Profit Margin(70.45) (76.01) 
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in womens sexual and reproductive health. Evofem Biosciences, Inc. is headquartered in San Diego, California. Evofem Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 147 people.

Current Evofem Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Evofem analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Evofem analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
4.25Buy4Odds
Evofem Biosciences current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Evofem analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Evofem stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Evofem Biosciences, talking to its executives and customers, or listening to Evofem conference calls.
Evofem Analyst Advice Details

Evofem Stock Analysis Indicators

Evofem Biosciences stock analysis indicators help investors evaluate how Evofem Biosciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Evofem Biosciences shares will generate the highest return on investment. By understating and applying Evofem Biosciences stock analysis, traders can identify Evofem Biosciences position entry and exit signals to maximize returns.
Quick Ratio0.65
Fifty Two Week Low0.7510
Shares Short Prior Month8.93M
Average Daily Volume Last 10 Day35.68M
Average Daily Volume In Three Month10.45M
Shares Percent Shares Out11.74%
Gross Margins17.49%
Short Percent Of Float13.76%
Forward Price Earnings-1.21
Float Shares81.07M
Fifty Two Week High5.5300
Enterprise Value To Ebitda-1.45
Fifty Day Average1.1085
Two Hundred Day Average2.2453
Enterprise Value To Revenue334.66
Continue to Investing Opportunities. Note that the Evofem Biosciences information on this page should be used as a complementary analysis to other Evofem Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Watchlist Optimization module to optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm.

Complementary Tools for Evofem Biosciences Stock analysis

When running Evofem Biosciences price analysis, check to measure Evofem Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evofem Biosciences is operating at the current time. Most of Evofem Biosciences' value examination focuses on studying past and present price action to predict the probability of Evofem Biosciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Evofem Biosciences' price. Additionally, you may evaluate how the addition of Evofem Biosciences to your portfolios can decrease your overall portfolio volatility.
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Equity Search
Search for activelly-traded equities including funds and ETFs from over 30 global markets
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
The market value of Evofem Biosciences is measured differently than its book value, which is the value of Evofem that is recorded on the company's balance sheet. Investors also form their own opinion of Evofem Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Evofem Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evofem Biosciences' market value can be influenced by many factors that don't directly affect Evofem Biosciences underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evofem Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Evofem Biosciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evofem Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.